相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。
Article
Medicine, General & Internal
Sivan Gazit et al.
Summary: This study compares the reinfection rate between previously infected individuals who were not vaccinated and those who received a single dose of the BNT162b2 vaccine. The results show that vaccination significantly reduces the risk of reinfection and symptomatic disease.
ANNALS OF INTERNAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Delphine Planas et al.
Summary: The Omicron variant of SARS-CoV-2, identified in November 2021, has spread rapidly worldwide and shows resistance to most therapeutic monoclonal antibodies and vaccine-elicited antibodies. However, it can be neutralized by antibodies generated by a booster vaccine dose.
Article
Biochemistry & Molecular Biology
Samuel M. S. Cheng et al.
Summary: Specific antibody levels against the SARS-CoV-2 Omicron variant decrease significantly after two doses of BNT162b2 or CoronaVac vaccines, but can be markedly increased with a booster dose of BNT162b2. Individuals who previously received two doses of BNT162b2 or CoronaVac showed reduced serum antibody titers against Omicron, while a BNT162b2 booster dose increased the antibody levels in the majority of individuals. This suggests mRNA vaccine boosters may be necessary in countries primarily using CoronaVac vaccines to combat the spread of Omicron.
Article
Biochemistry & Molecular Biology
Nick Andrews et al.
Summary: This study examined the relative and absolute effectiveness of mRNA booster vaccination against COVID-19. The results showed that the booster dose of BNT162b2 or mRNA-1273 had a relative effectiveness ranging from 85% to 95% against symptomatic disease, and an absolute effectiveness ranging from 94% to 97%. For hospitalization or death, the absolute effectiveness of the BNT162b2 booster ranged from 97% to 99% in all age groups. The study provides real-world evidence of significantly increased protection from the booster vaccine dose against mild and severe disease.
Article
Medicine, General & Internal
Victoria Hall et al.
Summary: This study investigated the duration and effectiveness of immunity among healthcare workers in the United Kingdom. It found that two doses of the BNT162b2 vaccine provided high short-term protection against SARS-CoV-2 infection, but this protection significantly decreased after six months. However, infection-acquired immunity boosted by vaccination remained high, even more than one year after infection.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Letter
Medicine, General & Internal
Shirley Collie et al.
Summary: Preliminary data from a test-negative study design in South Africa showed that two doses of the BNT162b2 vaccine had an efficacy of 50 to 70% against hospitalization caused by the omicron variant in Gauteng province.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Medicine, General & Internal
Ariel Hammerman et al.
Summary: This retrospective cohort study in Israel found that receiving at least one dose of the BNT162b2 vaccine was associated with a significantly lower risk of recurrent infection among patients who had recovered from Covid-19. Vaccine effectiveness was similar for one dose and two doses.
NEW ENGLAND JOURNAL OF MEDICINE
(2022)
Article
Immunology
Waleed H. Mahallawi et al.
Summary: The study recruited 136 participants, including 75 men and 61 women. Results showed that participants previously infected with SARS-CoV-2 showed significant anti-S IgG antibody levels after receiving either the Pfizer-BioNTech BNT162b2 mRNA or the Oxford-AstraZeneca ChAdOx1 COVID-19 vaccine. In participants aged 60 years and older, a second vaccine dose was necessary to achieve higher levels of antibody.
Article
Immunology
Sheila F. Lumley et al.
Summary: Natural infection with detectable anti-spike antibodies and two doses of vaccine provide robust protection against SARS-CoV-2 infection, including the B.1.1.7 variant in healthcare workers. Single dose vaccination significantly reduces the risk of symptomatic infection.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Cell Biology
Marit J. van Gils et al.
Summary: The study evaluated antibody responses following BNT162b2 vaccination in individuals previously infected with SARS-CoV-2. The results showed that a single dose of the vaccine administered within 15 months after SARS-CoV-2 infection produced higher levels of neutralizing antibodies compared to two vaccine doses in SARS-CoV-2-naive individuals.
CELL REPORTS MEDICINE
(2022)
Article
Infectious Diseases
Kamal Abu Jabal et al.
Summary: An analysis of 514 Israeli healthcare workers showed that the BNT162b2 mRNA COVID-19 vaccine had similar immunogenicity by ethnicity and sex, but decreased with age. Individuals with prior COVID-19 infection had significantly higher antibody titres compared to those who were naive, regardless of pre-vaccination IgG levels.
Letter
Medicine, General & Internal
Saman Saadat et al.
Summary: This study compared the titers of binding and neutralizing antibodies in healthcare workers previously infected with SARS-CoV-2 after receiving a single dose of mRNA coronavirus vaccine.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Letter
Medicine, General & Internal
Charlotte Manisty et al.
Article
Multidisciplinary Sciences
Zijun Wang et al.
Summary: Despite challenges posed by COVID-19 variants, convalescent individuals receiving mRNA vaccines exhibit robust and long-lasting immune responses against circulating SARS-CoV-2 variants, providing hope for effective control of the pandemic.
Article
Cell Biology
Daniel Lozano-Ojalvo et al.
Summary: The study found that the second dose of the vaccine increases immunity in naive individuals, while those who previously recovered from COVID-19 reach their peak immunity after the first dose. This suggests that a second dose may not be necessary for individuals who have been infected with SARS-CoV-2 before.
Article
Medicine, Research & Experimental
Alessio Mazzoni et al.
Summary: The study suggests that COVID-19-recovered individuals may not need a second vaccine dose to further enhance immune response, while naive individuals require a second dose for increased immunity. This indicates that redirecting vaccine doses from COVID-19-recovered individuals to naive individuals could shorten the time to achieve herd immunity.
JOURNAL OF CLINICAL INVESTIGATION
(2021)
